Agenus Inc. Common Stock (AGEN)
Stock · NASDAQ · Health Care
$6.04as of 10/16/2026
Price chart
Active signals
AGEN Signal Track Record
How signals performed across all stocks →What AGEN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -1.2% | 47% | September 28, 2026 |
| Bollinger Band Breakout | 23 | -9.1% | 26% | September 28, 2026 |
| Bollinger Band BreakdownActive now | 18 | -9.3% | 33% | May 18, 2026 |
| 200-Day Moving Average TouchActive now | 15 | +2.9% | 53% | April 27, 2026 |
| Any 20-session window (baseline) | -3.4% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AGEN
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also d…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 81
- Website
- agenusbio.com/
Fundamentals
- 1-day range
- $6$6.7
- Market cap
- $335.19M
- P/E (trailing)
- 3.19
- P/E (forward)
- -54.91
- EPS (trailing)
- $2.65
- Dividend yield
- —
- Beta
- 1.50
- Avg. volume
- 1.31M
How Agenus Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 16, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Agenus Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AGENAgenus Inc. Common Stock$6.04▼ 9.58%Market cap $335.19MP/E 3.19$2.71$10.31
- IPSCCentury Therapeutics Inc. Common Stock$1.37▼ 8.67%Market cap $342.67MP/E —$0.435$3.04
- IKTInhibikase Therapeutics Inc. Common Stock$1.65▼ 9.84%Market cap $318.20MP/E —$1.33$2.61
- LXEOLexeo Therapeutics Inc. Common Stock$2.64▼ 4.35%Market cap $357.27MP/E —$2.56$10.99
- CMPXCompass Therapeutics Inc. Common Stock$0.86▼ 4.12%Market cap $358.37MP/E —$0.8294$6.88
- PALIPalisade Bio Inc. Common Stock$1.41▼ 8.44%Market cap $362.78MP/E —$1.32$2.86
- AVXLAnavex Life Sciences Corp. Common Stock$1.31▼ 11.49%Market cap $303.96MP/E —$1.56$10.38
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AGEN Agenus Inc. Common Stock | $335.19M | 3.19 | $6.04 | ▼ 9.58% | $2.71$10.31 |
| IPSC Century Therapeutics Inc. Common Stock | $342.67M | — | $1.37 | ▼ 8.67% | $0.435$3.04 |
| IKT Inhibikase Therapeutics Inc. Common Stock | $318.20M | — | $1.65 | ▼ 9.84% | $1.33$2.61 |
| LXEO Lexeo Therapeutics Inc. Common Stock | $357.27M | — | $2.64 | ▼ 4.35% | $2.56$10.99 |
| CMPX Compass Therapeutics Inc. Common Stock | $358.37M | — | $0.86 | ▼ 4.12% | $0.8294$6.88 |
| PALI Palisade Bio Inc. Common Stock | $362.78M | — | $1.41 | ▼ 8.44% | $1.32$2.86 |
| AVXL Anavex Life Sciences Corp. Common Stock | $303.96M | — | $1.31 | ▼ 11.49% | $1.56$10.38 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Agenus to Participate in Chardan’s 10th Annual Healthcare Investor ConferenceYahoo · 10/9/2026
- Agenus Receives Marketion Authorization From Armenia For Botvymo To Treat Adult Patients With Microsatellite Stable Metastatic Colorectal Cancerbenzinga · 10/8/2026
- Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal CancerYahoo · 10/8/2026
- Agenus Receives Marketion Authorization From Armenia For Botvymo To Treat Adult Patients With Microsatellite Stable Metastatic Colorectal CancerBenzinga · 10/8/2026
- Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable PatientsBenzinga · 10/5/2026
- Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026Yahoo · 10/3/2026
- Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026Yahoo · 10/2/2026
- Agenus To Present Research On Botensilimab, Fc-Enhanced Multifunctional Anti-CTLA-4 Antibody, In Combination With Balstilimab, Anti-PD-1 Antibody, At SITC 2026Benzinga · 10/2/2026
- Agenus: Pivot To Neoadjuvant Setting In CRC Sends Stock Soaring - But Caution AdvisedSeekingAlpha · 9/29/2026
Insider Activity
Insider Actions →- Wright Timothy · October 1, 2026 · Grant1.2K
- Thomas L. Harrison · October 1, 2026 · Grant4.4K @ $6.89
- Garo H. Armen · August 10, 2026 · Grant1.97M
- Marcucci Marco Tullio · August 5, 2026 · Grant7.5K
- Susan B. Hirsch · August 5, 2026 · Grant50.0K
- Jennifer Buell · August 5, 2026 · Grant200.0K
- Thomas L. Harrison · August 5, 2026 · Grant50.0K
- Brian Corvese · August 5, 2026 · Grant100.0K
- Wright Timothy · August 5, 2026 · Grant50.0K
- O'Day Steven J · August 5, 2026 · Grant100.0K
- Garo H. Armen · July 10, 2026 · Grant4.9K @ $3.35
- Thomas L. Harrison · July 1, 2026 · Grant8.5K @ $3.58
- Wright Timothy · July 1, 2026 · Grant2.3K
- Garo H. Armen · June 12, 2026 · Grant4.9K @ $3.3
- Garo H. Armen · May 29, 2026 · Grant4.6K @ $3.5
Institutional Ownership
March 31, 2026
- Total shares held
- 7.95M
- Total value held
- $25.76M
- Institutional holders
- 83
- Unknown1.44M
- Unknown1.06M
- Unknown688.2K
- Unknown545.7K
- Unknown348.4K
- Unknown295.8K
- Unknown285.6K
- Unknown279.0K
- Unknown239.6K
- Unknown234.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Agenus Fair Value Adjusted Following Trial Updates and Financing
Agenus saw its estimated fair value rise after recent trial updates and new financing activities. These developments provide context for the stock's current position within its 52-week range. The news highlights ongoing corporate actions that may influence how analysts view the company's future prospects.
Agenus Fair Value Adjusted Following Trial Updates and Financing. Agenus saw its estimated fair value rise after recent trial updates and new financing activities. These developments provide context for the stock's current position within its 52-week range. The news highlights ongoing corporate actions that may influence how analysts view the company's future prospects.